-
1 Comment
Oncolys BioPharma Inc is currently in a long term downtrend where the price is trading 6.1% below its 200 day moving average.
From a valuation standpoint, the stock is 20.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 56.1.
Oncolys BioPharma Inc's total revenue sank by 83.9% to $107M since the same quarter in the previous year.
Its net income has dropped by 70.9% to $-550M since the same quarter in the previous year.
Based on the above factors, Oncolys BioPharma Inc gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| ISIN | JP3202170001 |
| Exchange | TSE |
| CurrencyCode | JPY |
| Market Cap | 25B |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.49 |
| Dividend Yield | None |
Oncolys BioPharma Inc. engages in the research, development, manufacturing, and sale of viral infectious disease treatment drugs in Japan, the United States, and Asia. The company offers Telomelysin (OBP-301), an oncolytic adenovirus, which is in Phase II clinical trial for the treatment of esophageal, gastric, and head and neck cancers, as well as hepatocellular carcinoma; and OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor, which is in Phase IIb clinical trial for the treatment of HIV infection. It also provides products in the pre-clinical trial stage, including OBP-2011, a compound for the treatment of SARS-CoV-2 virus infection; OBP-702, a telomerase-specific oncolytic adenovirus for the treatment of solid tumors; and OBP-801, a histone deacetylase inhibitor for the treatment of lung cancer, lymphoma, kidney cancer, and glaucoma, as well as TelomeScan (OBP-401 and OBP-1101), an adenovirus, which is in clinical study for detecting living circulating tumor cells. In addition, it is involved in the diagnostic, clinical testing, and inspection businesses. The company was incorporated in 2004 and is headquartered in Minato, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4588.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
